These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 33187914)

  • 1. Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
    Stenehjem DD; Lubinga SJ; Gupte-Singh K; Zhang Y; Le TK; Penrod JR; Smith CB
    Clin Lung Cancer; 2021 Jan; 22(1):e35-e47. PubMed ID: 33187914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
    Felip E; Ardizzoni A; Ciuleanu T; Cobo M; Laktionov K; Szilasi M; Califano R; Carcereny E; Griffiths R; Paz-Ares L; Duchnowska R; Garcia MA; Isla D; Jassem J; Appel W; Milanowski J; Van Meerbeeck JP; Wolf J; Li A; Acevedo A; Popat S
    Eur J Cancer; 2020 Mar; 127():160-172. PubMed ID: 32028209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
    Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
    Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
    Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
    Debieuvre D; Juergens RA; Asselain B; Audigier-Valette C; Auliac JB; Barlesi F; Benoit N; Bombaron P; Butts CA; Dixmier A; Gröschel A; Gutz S; Labbé C; Moro-Sibilot D; Pérol M; Raspaud C; Schumann C; Juarez-Garcia A; Lakhdari K; Pettersson F; Penrod JR; Reynaud D; Waldenberger D; Allan V; Sebastian M
    Lung Cancer; 2021 Jul; 157():40-47. PubMed ID: 33980420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
    Martin C; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Kowalyszyn R; Magri I; Varela M; Richardet E; Vera K; Foglia S; Jerez I; Aman E; Martinengo G; Batagelj E; Dri A; Pilnik N; Roa GM; Mando P; Tsou F; Recondo G; Cayol F; Flores M; Sena S; Bagnes C; Waisberg FD; Minatta JN; Rizzo M
    Clin Lung Cancer; 2020 Sep; 21(5):e380-e387. PubMed ID: 32213298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
    Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
    Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N;
    Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
    Ramagopalan S; Gupta A; Arora P; Thorlund K; Ray J; Subbiah V
    JAMA Netw Open; 2021 Nov; 4(11):e2134299. PubMed ID: 34767024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
    Molinier O; Besse B; Barlesi F; Audigier-Valette C; Friard S; Monnet I; Jeannin G; Mazières J; Cadranel J; Hureaux J; Hilgers W; Quoix E; Coudert B; Moro-Sibilot D; Fauchon E; Westeel V; Brun P; Langlais A; Morin F; Souquet PJ; Girard N
    ESMO Open; 2022 Feb; 7(1):100353. PubMed ID: 34953398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC.
    Wang Y; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Wu D; Long J; Zhang Z; Fang J
    Cancer Immunol Immunother; 2022 Feb; 71(2):267-276. PubMed ID: 34131807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice.
    Merino Almazán M; Duarte Pérez JM; Marín Pozo JF; Ortega Granados AL; Muros De Fuentes B; Quesada Sanz P; Gago Sánchez AI; Rodríguez Gómez P; Jurado García JM; Artime Rodríguez-Hermida F; Martínez Bautista MJ; Rueda Ramos A; Mora Rodríguez B; Martínez Díaz MC; Nieto Guindo P; Garrido Siles M; Villatoro Roldán R; Roldán Morales JC; Artacho Criado SM; Baños Roldán Ú; Inoriza Rueda Á; Garrido Martínez MT
    Int J Clin Pharm; 2019 Feb; 41(1):272-279. PubMed ID: 30578473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.
    Borghaei H; O'Byrne KJ; Paz-Ares L; Ciuleanu TE; Yu X; Pluzanski A; Nagrial A; Havel L; Kowalyszyn RD; Valette CA; Brahmer JR; Reck M; Ramalingam SS; Zhang L; Ntambwe I; Rabindran SK; Nathan FE; Balli D; Wu YL
    ESMO Open; 2023 Dec; 8(6):102065. PubMed ID: 37988950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
    Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
    Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
    [No Abstract]   [Full Text] [Related]  

  • 16. Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy.
    Kim J; Cho CK; Yoo HS
    Integr Cancer Ther; 2016 Dec; 15(4):467-477. PubMed ID: 27151594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
    Velcheti V; Hu X; Piperdi B; Burke T
    Sci Rep; 2021 Apr; 11(1):9222. PubMed ID: 33911121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network.
    Nadler E; Yu E; Ravelo A; Sing A; Forsyth M; Gruschkus S
    Oncologist; 2011; 16(4):486-96. PubMed ID: 21441299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung).
    Sebastian M; Gröschel A; Gütz S; Schulz H; Müller-Huesmann H; Liersch R; von der Heyde E; Wiegand J; Ukena D; Bargon J; Schütte W; Riera-Knorrenschild J; Fischer JR; Griesinger F; Allan V; Waldenberger D; Schumann C
    J Immunother; 2022 Feb-Mar 01; 45(2):89-99. PubMed ID: 34908007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea.
    Lim SM; Kim SW; Cho BC; Kang JH; Ahn MJ; Kim DW; Kim YC; Lee JS; Lee JS; Lee SY; Park KU; An HJ; Cho EK; Jang TW; Kim BS; Kim JH; Lee SS; Na II; Yoo SS; Lee KH
    Cancer Res Treat; 2020 Oct; 52(4):1112-1119. PubMed ID: 32599984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.